FDA chief blames decades of regulatory failure for misleading pharma ads
FDA chief Martin Makary said the agency will now ‘proactively monitor’ pharma companies for advertising law breaches.
Regulation
Five takeaway quotes from RFK Jr’s combative Senate hearing
FDA creates new pathway for rare disease drugs, analysts unconvinced
Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
Prasad’s shock FDA return reignites regulatory uncertainty
FDA publishes more than 200 archived CRLs for transparency
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
